CoChat

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Open access

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Background New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs. We assessed daratumumab, a novel CD38-targeted monoclonal antibody, in patients with refractory multiple myeloma. Methods In this open-label, multicentre, phase 2 trial done in Canada, Spain, and the USA, patients (age ≥18 years) with multiple myeloma who were previously treated with at least three lines of therapy (including proteasome inhibitors and immunomodulatory drugs), or were refractory to both proteasome inhibitors and immunomodulatory drugs, were randomly allocated in a 1:1 ratio to receive intravenous daratumumab 8 mg/kg or 16 mg/kg in part 1 stage 1 of the study, to decide the dose for further assessment in part 2. Patients received 8 mg/kg every 4 weeks, or 16 mg/kg per week for 8 weeks (cycles 1 and 2), then every 2 weeks for 16 weeks (cycles 3-6), and then every 4 weeks thereafter (cycle 7 and higher). The allocation schedule was computer-generated and randomisation, with permuted blocks, was done centrally with an interactive web response system. In part 1 stage 2 and part 2, patients received 16 mg/kg dosed as in part 1 stage 1. The primary endpoint was overall response rate (partial response [PR] + very good PR + complete response [CR] + stringent CR). All patients who received at least one dose of daratumumab were included in the analysis. The trial is registered with ClinicalTrials.gov, number NCT01985126. F…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(15)01120-4

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 854

Metadata

Authors
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., Mazumder, A., Orlowski, R. Z., Sutherland, H. J., Bladé, J., Scott, E. C., Oriol, A., Berdeja, J., Gharibo, M., Stevens, D. A., LeBlanc, R., Sebag, M., Callander, N., Jakubowiak, A., White, D., de la Rubia, J., Richardson, P. G., Lisby, S., Feng, H., Uhlar, C. M., Khan, I., Ahmadi, T., & Voorhees, P. M.
Affiliations
  • Emory University (US)
  • Abramson Cancer Center (US)
  • Carolinas Healthcare System (US)
  • Northwestern University (US)
  • Tisch Cancer Institute (US)
  • University of Calgary (CA)
  • Cross Cancer Institute (CA)
  • City Of Hope National Medical Center (US)
  • Cedars-Sinai Medical Center (US)
  • NYU Langone Health (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • University of British Columbia (CA)
  • Hospital Clínic de Barcelona (ES)
  • OHSU Knight Cancer Institute (US)
  • Josep Carreras Leukaemia Research Institute (ES)
  • Rutgers, The State University of New Jersey (US)
  • Norton Healthcare (US)
  • Hôpital Maisonneuve-Rosemont (CA)
  • University of Wisconsin–Madison (US)
  • University of Chicago (US)
  • Dalhousie University (CA)
  • Harvard University (US)
  • Genmab (Denmark) (DK)
  • Janssen Research & Development (United States) (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Lonial, Sagar
Venue
The Lancet
Publisher
Elsevier BV
Published
2016-04
Volume
387
Issue
10027
Pages
1551-1560
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2229483068
Cited by
854
References
25
Citations by year
2026: 18 · 2025: 38 · 2024: 42 · 2023: 68 · 2022: 73 · 2021: 111 · 2020: 121 · 2019: 93 · 2018: 95 · 2017: 114 · 2016: 77
FWCI
119.95
Type
journal article
Language
en
Open access
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • UNC Libraries
Funders
  • Amgen
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Sanofi
  • Spectrum Pharmaceuticals
  • Celgene
  • Karyopharm Therapeutics
  • Array BioPharma
  • Prothena
  • Pharmacyclics
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
daratumumab, multiple myeloma, overall response rate, progression-free survival, dose escalation, autologous stem cell transplantation, relapsed multiple myeloma, SIRIUS trial
MeSH terms
Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Canada, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Spain, United States, Treatment Outcome, Disease-Free Survival, Drug Resistance, Neoplasm, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(15)01120-4
The paper
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., Mazumder, A., Orlowski, R. Z., Sutherland, H. J., Bladé, J., Scott, E. C., Oriol, A., Berdeja, J., Gharibo, M., Stevens, D. A., . . . Voorhees, P. M. (2016). Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(15)01120-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.